FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

Details

Language :

English

ISSN :

23742437

Volume :

10

Issue :

6

Database :

Complementary Index

Journal :

JAMA Oncology

Publication Type :

Academic Journal

Accession number :

178024296

Full Text :

https://doi.org/10.1001/jamaoncol.2024.0207